The team at Cooley (UK) LLP boasts wide-ranging transactional experience, spanning cross-border mergers and acquisitions, SPAC deals, joint ventures, and divestitures. The group is chiefly instructed by clients from the life sciences and pharmaceuticals sectors, although its client base also covers the IT, fintech, and transport industries. Key figures in the team include tech sector specialist Ben Shribman, who is adept in cross-border M&A, growth capital fundraising, and venture capital transactions. Other notable names include Rita Sobral, Jarrett Burks, and Russell Anderson. Stephen Rosen, Justin Stock and David Bresnick left to join Akin in July 2024.
Testimonials
Collated independently by Legal 500 research team.
‘Very strong in early-stage companies and emerging technologies.’
‘Rita Sobral is committed, motivated, very savvy, and an excellent lawyer.’
‘The team at Cooley have always been strong with high-calibre individuals. The team are knowledgeable and know our sector very well.’
‘Ben Shribman is an exceptional M&A lawyer, he has the perfect balance of holding the line in his client's best interests, but also in being pragmatic to ensure the deal gets done and does not drag on unnecessarily. He is very responsive and efficient, always delivering on what he promises.’
‘Cooley in London has unique cross-border capabilities in the tech sector; there are very few firms offering the same breadth and depth in tech M&A, growth financing and IPOs. The London office is also bridging the gap between the US and Continental Europe.’
'Rita is definitely one of the up and coming superstars of the firm, with vast experience in the US, Latin America and Europe.’
Key clients
- Redx Pharma
- Amryt Pharma
- Unchained Labs
- Kpler
- Yandex
- VectivBio
- Bavarian Nordic
- Allergy Therapeutics
- Brain Labs
- Evox Therapeutics
- CovertSwarm
- TradingHub
- Snyk
- Adenza Holdings
- Toluna
Work highlights
- Assisted Amryt Pharma on its USD 1.48bn acquisition by Chiesi Farmaceutici.
- Advised Brainlabs on its investment from Falfurrias.
- Advised Evox Therapeutics on its acquisition of Codiak Biosciences’ engEx-AAV™ technology platform.